Eli Lilly
Entity.
- Evidence
- 448 documents · 131 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 6 May 2026, last seen 30 Oct 2026
- Measured
- 6% of mentions say something specific about it; the rest only name it
- As of
- 30 Oct 2026
Where this comes from
- Bitcoin News · 2026-10-29 · Walmart, Eli Lilly Among Latest Objectors to OKXICE Tokenized Stocks Platform (opens the source in a new tab)
- Endpoints News · 2026-10-29 · Lilly again far surpasses revenue expectations (opens the source in a new tab)
- an unnamed outlet · 2026-10-29 · Healthcare's AI race heats up (opens the source in a new tab)
- STAT News · 2026-10-28 · STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more (opens the source in a new tab)
- STAT News · 2026-10-28 · STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study (opens the source in a new tab)
- STAT News · 2026-10-28 · STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study (opens the source in a new tab)
- Psychedelic Alpha · 2026-10-28 · Pharma Moves In: Investors, Developers and Lilly’s Carole Ho at the Psychedelic Healthcare Forum (opens the source in a new tab)
- Clinical Trials Arena · 2026-10-28 · Lilly’s retatrutide beats Ozempic in head-to-head trial (opens the source in a new tab)
- Endpoints News · 2026-10-28 · Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes (opens the source in a new tab)
- an unnamed outlet · 2026-10-28 · Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss (opens the source in a new tab)
- 24/7 Wall St. · 2026-10-28 · 3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead (opens the source in a new tab)
- Endpoints News · 2026-10-27 · Lilly's ads can continue after Novo challenge, judge rules (opens the source in a new tab)
What is claimed about it
- Corroborated: Reported by three or more sources that did not copy each other.
- Single source: Reported by one source so far.
- Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss Corroborated · first reported 28 Oct 2026
- New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer Single source · first reported 24 Oct 2026